Literature DB >> 27013373

Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.

Jennifer A Chan1, Matthew H Kulke2.   

Abstract

When diagnosed at an early stage, resection of pancreatic neuroendocrine tumors (NETs) is often curative. Unfortunately, curative surgery is rarely an option for patients with metastatic disease. Multiple options are available for the management of patients with advanced pancreatic NETs, including surgery, liver-directed therapy, and systemic therapies. Because of the heterogeneity of disease biology and presentation, a multidisciplinary approach to management is critical. Treatment with somatostatin analogs, sunitinib, everolimus, and alkylating agents provide effective systemic therapeutic options for patients. Future studies to evaluate the optimal timing, sequence, and combination of therapies, as well as to identify predictors of response, are warranted.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Everolimus; Pancreatic neuroendocrine tumor; Somatostatin analogue; Sunitinib; Temozolomide; mTOR

Mesh:

Substances:

Year:  2016        PMID: 27013373     DOI: 10.1016/j.soc.2015.11.009

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  7 in total

Review 1.  Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis.

Authors:  Giandomenico Roviello; Laura Zanotti; Sergio Venturini; Alberto Bottini; Daniele Generali
Journal:  Cancer Biol Ther       Date:  2016-07-14       Impact factor: 4.742

2.  Neuroendocrine Tumors in Meckel's Diverticulum: Recommendation for Lymphadenectomy Regardless of Tumor Size Based on the NCDB Experience.

Authors:  Epameinondas Dogeas; Maximiliano Magallanes; Matthew R Porembka; Sam C Wang; Adam C Yopp; Patricio M Polanco; John C Mansour; Michael A Choti; Herbert J Zeh; Mathew M Augustine
Journal:  J Gastrointest Surg       Date:  2019-01-31       Impact factor: 3.452

3.  Prognostic significance of cytokeratin 19 expression in pancreatic neuroendocrine tumor: A meta-analysis.

Authors:  Dong Cen; Jiang Chen; Zheyong Li; Jie Zhao; Xiujun Cai
Journal:  PLoS One       Date:  2017-11-14       Impact factor: 3.240

Review 4.  Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors.

Authors:  Praveen Dilip Chatani; Sunita Kishore Agarwal; Samira Mercedes Sadowski
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-18       Impact factor: 5.555

Review 5.  Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy.

Authors:  Terry W Moody; Lingaku Lee; Irene Ramos-Alvarez; Tatiana Iordanskaia; Samuel A Mantey; Robert T Jensen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-01       Impact factor: 5.555

6.  Impact of Surgery on Non-Functional Pancreatic Neuroendocrine Tumors ≤2 cm: Analyses With Propensity Score-Based Inverse Probability of Treatment Weighting.

Authors:  Jingyuan Ye; Hongyu Wu; Jinzheng Li; Changan Liu
Journal:  Front Surg       Date:  2022-07-08

7.  PDGFRα expression as a novel therapeutic marker in well-differentiated neuroendocrine tumors.

Authors:  Elisabetta Cavalcanti; Antonia Ignazzi; Francesco De Michele; Maria Lucia Caruso
Journal:  Cancer Biol Ther       Date:  2018-10-22       Impact factor: 4.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.